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Abstract: Aim: A nested case-control discovery study was undertaken to test whether 
information within the serum peptidome can improve on the utility of CA125 for early ovarian 
cancer detection. Materials and Methods: High-throughput matrix-assisted laser desorption 
ionisation mass spectrometry (MALDI MS) was used to profile 295 serum samples from women 
pre-dating their ovarian cancer diagnosis and from 585 matched control samples. Classification 
rules incorporating CA125 and MS peak intensities were tested for discriminating ability. 
Results: Two peaks were found which in combination with CA125 discriminated cases from 
controls up to 15 and 11 months before diagnosis, respectively, and earlier than using CA125 
alone. One peak was identified as connective tissue-activating peptide III (CTAPIII), whilst the 
other was putatively identified as platelet factor 4 (PF4). ELISA data supported the down-
regulation of PF4 in early cancer cases. Conclusion: Serum peptide information with CA125 
improves lead time for early detection of ovarian cancer. The candidate markers are platelet-
derived chemokines, suggesting a link between platelet function and tumour development. 
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There are over 220,000 new cases of ovarian cancer worldwide each year (1). The disease has 
a poor prognosis mainly due to late diagnosis, with over 70% of patients exhibiting spread 
beyond the pelvis (2). Currently, ovarian cancer screening is not recommended due to lack of 
evidence of a mortality benefit, although large screening trials are underway to explore this 
issue in the low-risk population (3, 4). Strategies being tested combine serum cancer antigen 
125 (CA125) assay with transvaginal sonography (TVS). CA125 is a coelomic epithelium-
related glycoprotein of unknown function, secreted into the bloodstream by ovarian epithelial 
cells. However, CA125 is also produced by other mesothelium-derived tissues and may thus be 
elevated in benign gynaecological conditions and non-ovarian carcinomas, whilst not all early-
stage tumours generate CA125 (5). Consequently, the diagnostic accuracy of CA125 using a 
cut-off is sub-optimal and additional biomarkers to improve accuracy for screening and early 
detection of ovarian cancer are required (6). 
The performance characteristics required of an ovarian cancer biomarker depend upon the 
intended clinical use. Markers that can differentiate benign pelvic masses from malignancy in 
symptomatic women and guide surgical decisions need to improve upon existing tests which 
achieve sensitivities of 85-90% for detecting symptomatic ovarian cancer and specificities of 85-
90% for benign disease (7). Indeed, one such multi-marker test OVA1 (which includes CA125) 
was recently approved by the FDA (8). When combined with clinical assessment by imaging and 
physical examination, it achieves a sensitivity of >90% and a negative predictive value of 90% in 
women with an ovarian tumour. A more challenging clinical use is screening for ovarian cancer. 
This requires high sensitivity together with specificity in excess of 98% so that at least one in ten 
women who undergo surgery as a result of screen positive results (positive predictive value 
(PPV) >10%) has ovarian cancer. In the UK Collaborative Trial of Ovarian Cancer Screening 
(UKCTOCS) this was achieved in the prevalence screen by using CA125 interpreted using the 
risk of ovarian cancer (ROC) algorithm followed by TVS (3). While it is encouraging that 48% of 
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the cases detected were early-stage cancer, it does raise the need for improving lead time even 
when high sensitivity and specificity are achieved.  
Mass spectrometry (MS)-based proteomic profiling of polypeptides in serum (or plasma) 
holds promise for the identification of novel cancer biomarkers (9-11). However, serum 
proteome profiling is challenging due to the complexity and large dynamic range of abundance 
of its component proteins. Together with significant intra- and inter-individual heterogeneity, this 
has meant that few, if any, robust cancer biomarkers have been identified to date using 
proteomic methods. Indeed, most candidates reported have been abundant, non-specific acute-
phase proteins (12, 13) that are likely to be secondary host responses to any diseased state 
rather than specific markers useful for accurate diagnosis (14). In addition, numerous studies 
have highlighted alterations in serum and plasma proteins that are attributable to sample 
handling that is largely driven by differential proteolysis (15-21) (22). Finally, concerns have 
been raised over assay reproducibility and the robustness of class-discriminating algorithms 
used for proteomic profiling biomarker discovery (14, 23, 24). 
Matrix-assisted laser desorption/ionisation time-of-flight (MALDI-TOF) MS is a technique that 
can be used for high-throughput profiling of clinical samples, particularly when linked to 
automated handling. MALDI-TOF MS profiling has revealed the complexity of the low-molecular 
weight proteome (peptidome) of serum and plasma (25-27). Most peptides observed in MALDI-
TOF profiles are derived from relatively few abundant proteins as the result of extensive 
proteolysis, and it has been reported that these cleavage patterns can discriminate cancer 
cases from healthy controls (28). It was hypothesized that these peptide patterns are generated 
by tumour-specific exopeptidases during coagulation, and as such, represent ex vivo surrogate 
markers of cancer (28).  
In the present discovery study, we have used semi-automated peptide extraction linked to 
MALDI-TOF MS to profile the peptidomes of serum samples taken from the UKCTOCS trial. 
Samples were obtained from women at various timepoints prior to diagnosis of primary invasive 
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ovarian cancer and from healthy controls which were matched based on clotting time, collection 
centre and age. Given that these samples pre-date symptomatic cancer, they provide a unique 
source of early markers in the absence of late-stage confounding markers. We tested the power 
of peptide peaks alone and in combination with serum CA125 for discriminating cases from 
controls at different timepoints prior to diagnosis building on previous work from a pilot study 
where we reported that combining a single MS peak with CA125 allowed significant 
discrimination between cases and controls up to 12 months in advance of diagnosis (29). 
 
Materials and Methods 
Serum samples: A nested case-control study was undertaken on serum samples collected 
from 159 women who developed primary invasive ovarian cancer and 585 healthy women 
recruited to the UKCTOCS (30) (http://www.instituteforwomenshealth.ucl.ac.uk/ 
academic_research/gynaecologicalcancer/gcrc/ukctocs/design). This secondary study was 
approved by the Joint UCL/UCLH Research Ethics Committees on the Ethics of Human 
Research, Committee A (Ref. No. 05/Q0505/57) and written informed consent was obtained 
from all donors. No data allowing identification of patients was provided. There were 880 
samples in total collected between April 2001 and January 2007 at 13 trial centres, of which 295 
samples were from the 159 women who went on to develop ovarian cancer (referred to as 
cases). Of these there were single samples from 90 cases and up to 5 serial samples from 69 
cases. According to a standard operating procedure used at all centres, blood samples were 
taken by venepuncture into gel tubes (8 ml gel separation serum tubes; Greiner Bio-One, 
Stonehouse, UK) and transported by courier at ambient temperature to the central laboratory. 
All samples received more than 56 h after venepuncture were discarded and repeat samples 
requested. The blood was centrifuged at 1500 x g for 10 min, the serum separated and 
aliquoted into bar-coded straws which were frozen at –80°C and then transferred the next day 
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to liquid nitrogen for long-term storage. For each case the time to diagnosis was known, and is 
the time interval (measured in months) between the date of collection and the date of diagnosis 
(defined as the date of surgery/biopsy). Matched controls were 585 samples from healthy 
women with two samples matched per case (only 5 cases had 1 matched control). These were 
taken as close as possible in time to the case sample on the same day and at the same 
collection centre, and hence were clotted for the same time and stored identically as matched 
cases. Clotting times ranged between 1 and 49 h (average 23 h ± 4 h). Samples were also 
matched by age at sample draw as a secondary criterion if time and centre matching allowed.  
Baseline characteristics of cases and controls and statistical assessment of differences are 
presented in Table I. 
 
Sample preparation, MALDI-TOF MS profiling and data processing:  Blinded serum 
samples were subjected to pre-fractionation using robotic C18 ZipTip® (Billerica, MA, USA)  
reversed-phase extraction prior to automated MALDI-TOF MS data acquisition as described 
previously (31)-(32). Briefly, polypeptides were enriched from 5 µl of serum using a semi-
automated protocol based on reversed phase pre-packed tips (C18 ZipTips®). A CyBi®-Disk 
robot (CyBio AG, Jena, Germany) equipped with a 96-piston head for 25 µl tips was adapted 
and used for this purpose. After C18 ZipTip® purification, enriched polypeptides were eluted 
from the ZipTips®, and 2 µl from the eluate were mixed with α-cyano-4-hydroxycinnamic acid 
(CHCA) matrix and spotted onto a 600 µm-AnchorChip target plate (Bruker Daltonics, Bremen, 
Germany) for analysis on an Ultraflex II MALDI-TOF/TOF mass spectrometer (Bruker Daltonics) 
using FlexAnalysis v3.0 software (Bruker Daltonics) for further data handling. Up to 12 replicate 
mass spectra were generated for each sample giving 11,048 mass spectra in total. These were 
mass calibrated against peptide and protein standards run at the same time and converted to 
two column ASCII files of m/z values and corresponding intensities for further processing and 
analysis. Data processing steps (data reduction, smoothing, baseline subtraction, normalization, 
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peak defining and peak alignment) were applied to the data, as previously described (29). 
Documentation and Matlab system code for these steps are available at 
http://www.clrc.rhul.ac.uk/projects/proteomic3.htm. Following processing, a set of peak groups 
were defined, ordered and numbered according to their frequency of appearance in the dataset. 
The 67 most common peaks appearing in >33% of all spectra (cases and controls) were used 
for subsequent data analysis (Table II). Finally, the intensities of the 67 peaks were averaged 
across replicates for each sample. 
  
Classification and statistical testing: For classification, data from cases with only one 
matched control, and samples with a clotting time greater than 24 h were excluded, resulting in 
179 samples (from 104 cases) and 358 matched control samples organized into 179 triplets. A 
total of 59 cases had one measurement, 26 had 2 measurements, 11 had 3 measurements, 5 
had 4 measurements, and 3 had 5 measurements. Each triplet was assigned to a time to 
diagnosis group (in months) using a 6-month time window. Log-linear models using peak 
intensity were then tested for triplet classification, i.e. identification of the case sample within a 
triplet. Models were tested with and without CA125 values. For each triplet, the classification 
rule assigns a ‘case’ label to the sample with the largest value of w log C + v log I(p), where C 
and I(p) are the CA125 level and the intensity of peak p, respectively, and w and v are various 
weights (w={0, 0.5, 1, 2}; v={–1, 1}), the latter taking into account the direction of regulation of 
the peak in controls versus cases, logarithms were taken to remove the arbitrary units of 
measurements. Error rates were then calculated for various classification rules taking the peak 
giving the least number of errors. If two rules led to the same error rate, the rule involving the 
most frequently occurring peak across the dataset had priority when calculating P-values. 
In order to check the robustness of the triplet classification, three types of statistical tests 
were used which reject the following null hypotheses about the classification. (i) Assignment of 
the label ‘case’ within each triplet of each time group is random. We apply this hypothesis to 
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compare the performance of the classification rules on the actual data set with a randomly 
permuted data set. (ii) Assignment of labels within triplets is independent of CA125 levels – we 
wanted to check here if using CA125 alone is good enough to separate cases from controls. (iii) 
Peak intensities do not contain information useful to improve the predictive ability of CA125. 
Rejection of this third hypothesis means that separation between cases and controls is 
significantly improved after adding peak intensities to the information given by CA125. Based on 
the Monte-Carlo method, we developed a procedure to calculate P-values (see (29)) for the first 
null hypothesis. Here, the test statistic is calculated a large number of times (N) for the data set 
with a randomly assigned label ‘case’ within each triplet, and counting the number of times (Q) 
this statistic is equal to or less than the actual statistic computed from the observed data set. 
The P-value is then estimated as Q/N. For the second null hypothesis, the error rate was 
computed using CA125 only (i.e. v=0). For the third null hypothesis, the same set of 
classification rules is used as for the first null hypothesis, but instead of randomly assigning the 
‘case’ label, we randomly permute the three peak intensities within each triplet (6 possible 
permutations), leaving the labels and CA125 levels as they are. All three procedures produce 
valid P-values that do not need adjustment in the sense that for each threshold δ the probability 
that the computed P-value does not exceed δ will be at most δ (under the null hypothesis). A 
detailed account of the corresponding P-value calculations using the Monte-Carlo method, their 
meanings and validity is described in Supplementary Information 1 (see also (29). 
 
Peak identification: MALDI-TOF MS peaks were identified using 96 pooled UKCTOCS sample 
eluates from C18 ZipTip® extraction as a source of material and a combination of MALDI 
MS/MS, ESI MS/MS and off-line LC fractionation and ESI MS/MS with or without tryptic 
digestion The methodology (see (27)) was designed to ensure that identifications could be 
directly linked to the relevant peak by confirming the presence of that peak in fractions at each 
stage of the procedure by MALDI-TOF MS. 
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For peak identification using MALDI MS/MS, the pooled eluates were mixed in a ratio of 1:1 
(v:v) with either 5 mg/ml CHCA or 50 mg/ml 2,5-dihydroxybenzoic acid (DHB) matrix prepared 
in 50% acetonitrile (ACN)/0.1% trifluoroacetic acid (TFA) and spotted onto a MALDI target plate 
for analysis on a Q-TOF Premier (Waters, Manchester, UK) equipped with a 337 nm-UV-MALDI 
source. For peak identification using ESI MS/MS, the pooled eluates were first dried, then 
resuspended in 50% ACN/0.1% formic acid and sprayed using a Nanomate HD (Advion 
Biosciences, Ithaca, NY, USA) as nanoESI ion source in front of the Q-TOF Premier. A positive 
voltage of 1.7 kV was applied to the chip and the flow rate was kept constant at ~80 nl/min. At 
this flow rate, a sample volume of 10 µl provided stable static electrospray for at least 2 h. 
For peak identification using off-line LC fractionation and ESI MS/MS, 100 µl of the pooled 
eluate was loaded onto a HiChrom ACE C18 column (2.1mm ID, 150 mm length) (HiChrom 
Ltd., Reading, UK), pre-equilibrated with 5% ACN/0.1% formic acid (FA) and using an Agilent 
1100 LC system (Agilent Technologies inc., Santa Clara, CA, USA). Elution was achieved using 
a binary solvent gradient of 5-70% ACN in 0.1% FA at a flow rate of 100 µl/min over 90 min, and 
finally up to 95% ACN/0.1% FA in 10 min. UV detection was set at 214 nm with fractions 
collected every minute. Fractions were dried and resuspended in 40 µl of 50% ACN/0.1% FA, 
then 15 µl was taken for chip-based nanoESI analysis using the Nanomate and Q-TOF Premier, 
2 µl were used for MALDI-TOF analysis (Ultraflex), and the remaining was dried before 
resuspension in 15 µl of trypsin solution (100 ng trypsin in 100 mM ammonium bicarbonate, pH 
8.5) and incubation overnight at 37°C. Finally, digested fractions were subjected to C18 
ZipTips® clean-up as detailed above for MALDI-TOF MS profiling, except that the elution was 
performed using 10 µl of 50% ACN/0.1% FA. The purified digested fractions were then loaded 
on the Nanomate system and nanoESI MS/MS data were collected using data dependent 
acquisition. 
Identification of peptides was performed by searching against the human protein sequence 
library in NCBInr (v20081128, 216937 sequences) using the Mascot 2.2 search engine (Matrix 
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Science, London, UK). Searches were performed choosing “None” for enzyme (“Trypsin” for the 
digested fractions) and with a mass tolerance of 0.1 Da for parent ions and 0.2 Da for fragment 
ions. “Ammonia-loss (N-term C)”, “Deamidated (NQ)”, “Dehydrated (N-term C)”, “Oxidation (M)”, 
“Phospho (ST)”, and “Phospho (Y)” were set as variable modifications. GPMAW software v7.10 
(Lighthouse data, Odense, Denmark) was used to match accurate mass data obtained from 
undigested samples with theoretical peptide masses of protein hits obtained from the MASCOT 
analysis of the MS/MS data of the digested fractions. Isotope pattern software v3.0 (Bruker 
Daltonics) was used for comparison of experimental isotopomer distributions with the theoretical 
distribution from putative peptide identifications and the UniProt and NCBI protein databases 
were used to extract additional information for substantiating or rejecting putative identities, e.g. 
information with regard to alternative splicing, pro-sequence cleavage, disulfide bridges and 
post-translational modifications. 
  
CA125 and PF4 immunoassays: CA125 analysis was performed using an electro-
chemiluminescence immunoassay on a Roche Elecsys 2010 analyser (Roche Diagnostics, 
Burgess Hill, UK). The assay uses monoclonal antibodies OC125 as the detection antibody and 
M11 as the capture antibody (Fujirebio Diagnostics; Oxford Biosystems, Oxford, UK). PF4 
assays were performed on 173 of the case samples and 173 matched controls using an 
Asserachrom PF4 ELISA kit (Diagnostica Stago UK Ltd). Serum samples were diluted 1:2,100 
v/v with dilution buffer and assayed according to the manufacturer's instructions. 
 
Results 
Peak discovery: MALDI MS profiling of a set of blinded ovarian cancer pre-diagnosis sera and 
matched controls from UKCTOCS was conducted to identify possible candidate markers for 
early detection. Raw MS spectral data were processed (Figure 1A) and classification rules 
applied to peak intensity information and CA125 values and these tested for significance. Given 
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the limited number of samples, 6-month time slots starting in different months with cases and 
two matched controls grouped into triplets were considered. For each time slot, hypotheses of 
random label distribution were tested, calculating P-values and looking for peaks carrying 
information for discriminating pre-diagnosis cancer cases from matched controls. Using single 
peak information alone, several of the 67 peaks analysed (Table II) were able to discriminate 
cases from controls at a confidence level of P<0.05, and mostly at the early time slots (Table 
III). However, none provided significant discrimination after adjustment for multiple testing. 
Peak information was next combined with CA125 values to examine if any peaks could 
improve on CA125 in terms of early detection. The expected probability of error in triple 
classification is 2/3, so misclassifying 16 out of 30 triplets (as for the 13 month time group) was 
not significant (P=0.09), but still better than random (Table IV). The results for classification 
using CA125 alone were significant up to 9 months before diagnosis, an important finding. 
When peak information was added, the classification was improved, with the lead time of 
detection significant (P<0.05) up to 15 months prior to diagnosis, with the only exception being 
the 12 months time group with a P-value of 0.059. Peaks with processed m/z values of 7772 
and 9297 (referred to as peaks 2 and 3 based on their frequency of occurrence) were used 
most often for discrimination of cases and controls at these earlier time slots. The spectral 
profiles of these peaks are shown in Figure 1B. None of these P-values require adjustment as 
they satisfy the property of validity described in the Materials and Methods. However, they do 
not demonstrate the significance of individual peaks; they only show that the peaks are 
significant en masse. A further P value was thus calculated. Whereas the overall ‘main’ P-value 
tests the hypothesis that CA125 and peak intensity do not help to discriminate cases from 
controls, the ‘conditional’ P-values presented in Table 5 test the hypothesis that given CA125, 
the peaks do not carry additional information useful for discrimination. For this analysis, the 
conditional P-values are more important, since it is known that CA125 is a useful biomarker and 
therefore the interest is in whether addition of other data leads to significant improvement. The 
 12 
conditional P-values show that the contribution of adding MS peaks becomes essential only 
from 10 to 15 months. 
The significance of peaks 2 and 3 were next checked directly by adjusting the main and 
conditional P-values using the sets of rules with these peak numbers built in. Table V presents 
the results for prediction by CA125 and peak 2 (columns 5–8), and by CA125 and peak 3 
(columns 9–12). Error rate and P-value for prediction using CA125 alone are included in the 
table for comparison. The ‘rule’ columns show the best rules selected. As above, the conditional 
P-values show that improvement on CA125 cannot be achieved by adding information from 
either peak 2 or 3 up to 9 months before diagnosis, but that these peaks do improve its 
predictive ability beyond 9 months. Indeed, the results are significant for up to 15 months using 
peak 2 and 11 months using peak 3. The main and conditional P-values given in Table V have 
been adjusted for multiple hypothesis testing (see (33) and Lemma 2 in Supplementary 
Information 1). Figure 2 illustrates the performance of the best classification rules log C − 2 log 
I(2) and log C − log I(3), respectively, in comparison with the performance of log C. The 
horizontal axis shows time to diagnosis, the vertical axis triplet groups in this time interval. The 
figures demonstrate that most triplets with the measurement date close to diagnosis date are 
predicted correctly even by the log C rule and that most samples where addition of a peak to 
CA125 allows correct classification (marked as up-directed triangles) are in the interval of 13–16 
months prior to diagnosis. Figure 3 shows the median dynamics of these rules for case 
measurements. For each time moment, the latest available case measurement for each triplet 
group is taken into account. These measurements are averaged by median through all triplet 
groups. The figures illustrate that the values from the rules combining CA125 with peak intensity 
are elevated earlier than when using CA125 alone and that this is followed by the exponential 
growth of CA125 closer to diagnosis. Notably, combining both peaks with CA125 did not 
improve the accuracy compared to the single peak models. 
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Peak identification: Identification of peak 3 (m/z 9297) was achieved using a thoroughly 
executed fractionation and MS-based analysis of UKCTOCS samples, ensuring that the peak of 
interest was retained after each preparation step (27). Briefly, MALDI MS spectra were acquired 
before fractionation and for each fraction. These were compared with ESI MS spectra for all 
fractions, making sure that the major peaks also appear as major peaks within the respective 
ESI MS spectra. The fractions in which peak 3 was obtained were also digested and further 
analysed by MS/MS. From this analysis, three peptides were obtained that identified connective 
tissue-activating peptide III (CTAPIII) as the major component of the relevant fractions. CTAPIII 
is a bioactive cleavage product of platelet basic protein/C-X-C motif chemokine 7. As also both 
MALDI and ESI MS of the undigested fractions revealed that the peak(s) close in mass to 
CTAPIII account for the main ion signal intensities in these spectra, it can be concluded that 
within these fractions, the MALDI MS peak 3 is in fact CTAPIII. Figure S1 in the Supplementary 
Information shows example spectra acquired throughout the analysis. In addition, using 
GPMAW software for matching sequences to m/z values obtained from the ESI MS spectra, we 
found only CTAPIII (full sequence) to fit the obtained MS peak. For further confirmation, we also 
generated the theoretical isotopic distribution of CTAPIII which matched closely to that found 
experimentally. Despite intensive effort, peak 2 (m/z 7772) eluded identification using these 
methods. Instead, we have relied on literature searches and the fact that the peak is relatively 
isolated in spectra and frequently occurring (Table II). The identity of peak 2 as platelet factor 4 
(PF4/CXCL4; average molecular weight 7769.18 Da) was thus inferred from two studies where 
it was identified by off-line LC fractionation and ESI MS/MS following SELDI-TOF MS serum 
profiling (34) and by immuno-capture after MALDI-TOF MS serum profiling (35). Although 
inferred, it is highly likely that peak 2 in our samples represents the chemokine PF4. 
 
Verification: In an attempt to verify the PF4 data, an ELISA was used to measure its levels in 
173 of the case samples and 173 matched controls, and associations with case control status, 
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time to diagnosis, clotting time, tumour stage, age, hormone replacement therapy (HRT) use 
and CA125 level were examined. There was no significant difference when all cases and 
controls were compared with median values of 6,958 IU/ml (range=1,642-15,096) for cases and 
6,847 IU/ml (range=1,610-15,223) for controls (P=0.69). However, PF4 levels were significantly 
lower in cases in the 6-12 and 12-24 months time to diagnosis groups versus those in the 0-6 
months time group, with P-values of 0.037 and 0.012, respectively (Figure 4A). There was also 
a trend for lower PF4 levels in cases versus controls in the distant time groups, but these were 
not significant at the 95% confidence level. There was no difference in PF4 level with HRT use, 
age or clotting time, whilst samples from cases with stage IV tumours at diagnosis had lower 
levels of PF4 versus those with other stages (e.g. P=0.027 versus stage I) and controls (e.g. 
P=0.013 versus all controls). Finally, there was a clear rise in CA125 in cases in the lead up to 
diagnosis (Figure 4B), whereas PF4 showed no consistent change (Figure 4C). There was no 
correlation between PF4 and CA125 levels for either the case or control groups (Figure 4D), 
although examination of only samples with low CA125 (<30 U/ml) did reveal lower PF4 levels in 
cases versus controls that approached significance (P=0.065). 
 
Discussion 
The purpose of this study was to assess if low mass serum polypeptides carry information to aid 
in the early diagnosis of ovarian cancer. We showed that two MALDI peaks (identified as 
CTAPIII and inferred as PF4, respectively), when combined with serum CA125, provided 
significantly earlier detection of cancer. CA125 alone gave significant prediction up to 9 months 
prior to diagnosis, similar to a previous report (36), with MS peak information not adding 
significantly to this. At greater than 9 months prior to diagnosis, CA125 performance was 
significantly complemented by adding MS peak information, with confident detection up to 15 
months using all peaks and 15 and 11 months using peaks 2 and 3, respectively. 
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We wanted to confirm the altered expression of these peaks using orthogonal assay 
methods. Peak 2, speculatively identified as PF4, was assayed using a commercial ELISA. 
There was no significant difference between cases and controls when all samples were 
considered, but levels of PF4 were lower in distant versus proximal cases, as well as there 
being a trend for lower PF4 in cases versus controls at the distant time points, and in women 
later diagnosed with stage IV cancer. Whilst not confirmatory from a statistical standpoint, these 
data give some support for reduced serum PF4 levels early in cancer development. For 
CTAPIII, there were no suitable immunoassays available which would be specific for CTAPIII 
without also recognising the nine other processed products of platelet basic protein with their 
overlapping sequences i.e. TC-2, CTAPIII(1-81), beta-thromboglobulin, neutrophil-activating 
peptide 2 (NAP2)(74), NAP2(73), NAP2, TC-1, NAP2(1-66) and NAP2(1-63). 
CTAPIII is a chemokine released into the circulation from platelet alpha granules. It is known 
to stimulate DNA synthesis, mitosis, glycolysis, intracellular cAMP accumulation, prostaglandin 
E2 secretion and synthesis of hyaluronic acid and sulfated glycosaminoglycan in target tissues. 
PF4 is also released from platelet alpha granules and possibly leukocytes and has a major role 
in neutralising the anticoagulant effect of heparin through binding. It is also chemotactic for 
neutrophils and monocytes and inhibits endothelial and activated T-cell proliferation. From our 
data, it would appear that the secretion of both chemokines is suppressed in the early stages of 
ovarian cancer possibly through a host response to tumour development. This suppression may 
support tumour growth through the modulation of inflammatory and immunogenic processes, 
coagulation and angiogenesis, and as such may not be specific to ovarian cancer (see below).  
Perhaps a weakness of this study is the fact that CA125 was used as part of the diagnostic 
procedure making interpretation of results for a combined biomarker panel difficult. However, 
limiting the analysis to only those cases which were screen negative and who developed 
symptomatic disease would greatly diminish the value of this unique preclinical sample set and 
the impact of the study. Although the median age was significantly different between the sample 
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groups (P=0.01), it has no clinical significance in this post-menopausal population. It is known 
that HRT use is a risk factor for ovarian cancer (37) and also that HRT use can have a profound 
effect on the serum proteome (38). However, there was no significant difference in HRT use 
between the case and control groups used here (Table I) and indeed no correlation between 
HRT use (or age) and PF4 level (measured by ELISA). We thus conclude that HRT use is not a 
confounding factor in this study. The other significant difference between the groups was in the 
use of the oral contraceptive pill (P=0.005), which was higher in the control group. This may be 
expected as the pill is known to confer long-term protection against ovarian cancer (39). 
It has been proposed that tumour-specific exopeptidases may generate surrogate peptide 
markers of cancer ex vivo during coagulation (28). Despite this, we recently showed that such 
peptides do not make useful biomarkers for ovarian cancer diagnosis (32). This result seems at 
odds with the findings of the present study. However, it is important to note that both CTAPIII 
and PF4 are released into the circulation in their processed forms and appear not to arise or be 
subject to proteolysis during serum preparation: we have found no evidence that smaller 
fragments of these proteins are generated (27) that may explain their reduced levels in pre-
diagnosis sera. We therefore hypothesise that these proteins are altered in the earlier stages of 
tumour development but do not maintain differential expression close to diagnosis. This may 
explain why we failed to identify changes in these proteins in serum samples from clinically 
diagnosed cases and controls using the same profiling strategy (32) (40). Here no models 
incorporating peak intensities were accurately able to discriminate cases from benign or healthy 
controls, and peak information failed to add to the performance of CA125. 
Although a diagnostic test for ovarian cancer based on SELDI-TOF MS assays, includes 
CTAPIII as an up-regulated protein (8) (41), we have failed to reproduce this using the same 
strategy (unpublished data). Notably, both CTAPIII and PF4 have been identified as putative 
biomarkers down-regulated in serum samples from acute lymphoblastic leukaemia cases where 
they were similarly identified by off-line LC fractionation and ESI-MS/MS following SELDI-TOF 
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MS profiling (34). PF4 was also identified from MALDI-TOF MS serum profiling experiments as 
a putative biomarker of pancreatic cancer and was shown also to be down-regulated in the 
samples from cases (35). Although this data implies the poor specificity of these proteins in 
detecting ovarian cancer, it does support their possible negative roles in cancer progression. 
In conclusion, our discovery study shows that the period of significant discrimination in 
advance of diagnosis can be extended from 9 to 15 months if CA125 is combined with certain 
MALDI MS peaks which we identify as the chemokine CTAPIII and putatively as the chemokine 
PF4. This data supports a link between platelet function and tumour development in the early 
stages of ovarian cancer. Further work will be required to validate these findings to assess the 
potential of these markers for early ovarian cancer detection. 
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Tables 
 
Table I. Baseline characteristics of cases and controls with significance testing.  
 
Median (25th - 75th centiles) P-value 
Baseline characteristics 
Controls (n=585) Cases (n=159) Mann-Whitney test 
Age (years) at randomisation 59.8 (55.6-65.2) 61.7 (57.3-66.4) 0.01 
Age at last period (years) 50.1 (46.8-52.7) 50.7 (46.2-52.6) 0.873 
Duration of HRT use in those on 
HRT at randomisation (years) 7.8 (4.5-10.7) 8.9 (4.8-13.8) 0.263 
Duration of OCP use (years) in 
those who had used it 5 (2-10) 5 (2-10) 0.639 
Miscarriages (pregnancies <6 
months) 0 (0-1) 0 (0-1) 0.656 
No. of children (pregnancies >6 
months) 2 (2-3) 2 (1-3) 0.167 
Height (cm) 162.6 (157.5-165.1) 162.6 (157.5-167.6) 0.809 
Weight (kg) 67.1 (60.8-76.2) 68.7 (60.3-76.2) 0.601 
  
Number (%) Fisher's exact test 
Ethnicity:     0.59 
    White 571 (97.6%) 155 (97.5%)   
    Black  4 (0.7%) 0 (0.0%)   
    Asian  5 (0.9%) 2 (1.3%)   
    Other 2 (0.3%) 1 (0.6%)   
    Missing 3 (0.5%) 1 (0.6%)   
Hysterectomy  101 (17.3%) 27 (17.0%) 1.000 
Ever use of OCP 327 (55.9%) 69 (43.4%) 0.005 
Use of HRT at recruitment 126 (21.5%) 41 (25.8%) 0.284 
Maternal history of ovarian cancer  30 (5.1%) 5 (3.1%) 0.693 
Maternal history of breast cancer  102 (17.4%) 31 (19.5%) 0.450 
 
HRT, Hormone replacement therapy; OCP, oral contraceptive pill. 
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Table II. List of the 67 most frequently occurring MALDI MS peaks in the dataset showing their 
peak number assignment, processed m/z values and frequency of occurrence. 
 
Peak 
number 
m/z 
Value 
(Da) 
Frequency 
(out of 
11048) 
Peak 
number 
m/z 
Value 
(Da) 
Frequency 
(out of 
11048) 
1 4213.4 11043 35 1704.5 7292 
2 7772.1 11040 36 992.2 7109 
3 9297.8 11040 37 2084.5 7048 
4 5341 11036 38 9724.2 6658 
5 5909.2 11029 39 5583.3 6570 
6 6636 10994 40 4285.7 6517 
7 4647.8 10904 41 2993.5 6460 
8 4057.2 10878 42 2606 6422 
9 3243.9 10739 43 2274.3 6358 
10 3959 10705 44 740.9 6349 
11 4967.9 10682 45 2512.8 6345 
12 3772.6 10609 46 4759.2 6193 
13 2757.3 10596 47 3527 6005 
14 8610.9 10537 48 1742.6 5873 
15 8937.3 10437 49 3161.7 5591 
16 4478.8 10393 50 3886.1 5586 
17 2662.9 10367 51 6385.4 5361 
18 1547.6 10222 52 1262.6 5188 
19 5007.8 10174 53 853.1 5001 
20 2381.1 10088 54 1790 4910 
21 3510.1 9870 55 6810 4909 
22 6437.3 9819 56 7476.7 4859 
23 2356.4 9749 57 905.9 4733 
24 2025.7 9274 58 1041.2 4627 
25 8135.7 9195 59 2191.2 4583 
26 2116.6 9140 60 1618.2 4304 
27 1946.9 9042 61 870.1 4298 
28 1467.7 9024 62 2871.2 4294 
29 2935.4 8984 63 3266.5 4191 
30 1450.7 8545 64 6231.3 3841 
31 1016.7 8432 65 1278.4 3724 
32 2212.2 8034 66 3616.4 3683 
33 1898.9 7797 67 1115.1 3650 
34 3194.8 7599    
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Table III. Statistical analysis of peaks for discrimination of cases and controls. P-values are 
presented for each of 67 peaks distributed by time-to-diagnosis time slots (t + 6 months prior to 
diagnosis). P-values of <0.05 are indicated in bold italics. For adjusted P-values a threshold of 
0.05/67= 0.00075 should be considered as significant at the 95% confidence level. 
t 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
No. cases 68 56 47 36 27 23 20 17 17 20 28 28 28 30 25 20 
Peak 1 0.507 0.299 0.188 0.427 0.567 0.515 0.330 0.722 0.080 0.192 0.467 0.462 0.471 0.279 0.624 0.520 
2 0.714 0.626 0.185 0.560 0.269 0.352 0.091 0.335 0.174 0.193 0.009 0.021 0.103 0.045 0.042 0.042 
3 0.506 0.407 0.195 0.290 0.723 0.689 0.185 0.333 0.529 0.341 0.051 0.107 0.308 0.093 0.045 0.094 
4 0.162 0.086 0.074 0.190 0.575 0.678 0.515 0.525 0.175 0.195 0.304 0.309 0.455 0.409 0.627 0.702 
5 0.112 0.008 0.071 0.194 0.411 0.823 0.700 0.868 0.331 0.093 0.309 0.191 0.183 0.089 0.171 0.519 
6 0.067 0.086 0.189 0.185 0.268 0.216 0.198 0.327 0.173 0.527 0.188 0.102 0.103 0.282 0.628 0.520 
7 0.865 0.934 0.907 0.998 0.993 0.974 0.942 0.871 0.533 0.524 0.108 0.185 0.310 0.171 0.183 0.097 
8 0.160 0.297 0.512 0.704 0.930 0.696 0.520 0.326 0.330 0.094 0.023 0.021 0.024 0.043 0.040 0.088 
9 0.312 0.395 0.287 0.297 0.409 0.822 0.941 0.959 0.872 0.521 0.191 0.048 0.048 0.044 0.088 0.197 
10 0.788 0.886 0.843 0.571 0.734 0.525 0.516 0.717 0.528 0.339 0.625 0.944 0.946 0.827 0.887 0.937 
11 0.157 0.207 0.287 0.419 0.583 0.690 0.711 0.722 0.718 0.339 0.104 0.053 0.099 0.285 0.312 0.519 
12 0.316 0.516 0.523 0.420 0.578 0.688 0.715 0.874 0.871 0.849 0.619 0.466 0.624 0.713 0.775 0.701 
13 0.513 0.405 0.285 0.560 0.570 0.826 0.847 0.724 0.864 0.849 0.468 0.188 0.189 0.165 0.182 0.187 
14 0.970 0.963 0.837 0.699 0.417 0.109 0.344 0.713 0.712 0.523 0.625 0.758 0.625 0.571 0.631 0.851 
15 0.618 0.729 0.191 0.110 0.039 0.103 0.199 0.524 0.526 0.852 0.873 0.764 0.623 0.837 0.786 0.701 
16 0.853 0.985 0.909 0.421 0.569 0.359 0.528 0.529 0.719 0.852 0.761 0.940 0.942 0.839 0.776 0.702 
17 0.985 0.993 0.988 0.895 0.929 0.927 0.941 0.532 0.327 0.334 0.463 0.308 0.194 0.278 0.459 0.347 
18 0.945 0.879 0.840 0.704 0.724 0.524 0.524 0.710 0.720 0.855 0.769 0.763 0.628 0.282 0.304 0.091 
19 0.612 0.634 0.639 0.423 0.850 0.697 0.342 0.332 0.720 0.516 0.471 0.622 0.865 0.830 0.785 0.846 
20 0.408 0.812 0.640 0.693 0.851 0.923 0.846 0.719 0.872 0.847 0.768 0.464 0.467 0.712 0.779 0.704 
21 0.312 0.933 0.947 0.979 0.575 0.832 0.941 0.530 0.713 0.519 0.186 0.190 0.193 0.412 0.301 0.340 
22 0.612 0.624 0.633 0.694 0.406 0.205 0.042 0.079 0.172 0.193 0.320 0.104 0.194 0.287 0.463 0.524 
23 0.408 0.821 0.747 0.977 0.927 0.993 1.000 0.962 0.875 0.849 0.874 0.765 0.762 0.912 0.955 0.946 
24 0.795 0.809 0.637 0.810 0.925 0.972 0.855 0.875 0.528 0.701 0.630 0.460 0.623 0.572 0.890 0.848 
25 0.611 0.517 0.836 0.293 0.268 0.518 0.524 0.327 0.169 0.340 0.053 0.101 0.186 0.277 0.184 0.096 
26 0.795 0.934 0.946 0.814 0.847 0.836 0.707 0.528 0.524 0.333 0.471 0.626 0.871 0.835 0.893 0.942 
27 0.704 0.727 0.951 0.899 0.931 0.688 0.700 0.718 0.532 0.703 0.763 0.870 0.765 0.408 0.454 0.338 
28 0.607 0.299 0.630 0.696 0.567 0.832 0.845 0.954 0.724 0.853 0.881 0.874 0.767 0.567 0.771 0.527 
29 0.791 0.879 0.946 0.816 0.924 0.921 0.849 0.863 0.720 0.700 0.761 0.771 0.876 0.563 0.463 0.527 
30 0.910 0.813 0.384 0.899 0.724 0.519 0.850 0.952 0.875 0.943 0.768 0.624 0.469 0.175 0.177 0.038 
31 0.107 0.028 0.039 0.111 0.417 0.204 0.340 0.524 0.870 0.940 0.944 0.942 0.876 0.917 0.885 0.712 
32 0.611 0.517 0.836 0.293 0.268 0.518 0.524 0.327 0.169 0.340 0.053 0.101 0.186 0.277 0.184 0.096 
33 0.418 0.510 0.636 0.555 0.570 0.048 0.200 0.519 0.314 0.524 0.313 0.762 0.772 0.415 0.459 0.336 
34 0.320 0.135 0.502 0.820 0.727 0.973 0.938 0.989 0.873 0.523 0.192 0.101 0.195 0.089 0.091 0.196 
35 0.857 0.887 0.903 0.296 0.576 0.525 0.333 0.328 0.323 0.519 0.626 0.625 0.876 0.710 0.774 0.704 
36 0.857 0.811 0.639 0.420 0.847 0.521 0.709 0.871 0.989 0.997 0.878 0.622 0.459 0.420 0.301 0.095 
37 0.908 0.883 0.953 0.950 0.723 0.693 0.702 0.723 0.529 0.707 0.624 0.768 0.871 0.712 0.770 0.704 
38 0.621 0.981 0.642 0.188 0.257 0.209 0.201 0.181 0.335 0.705 0.877 0.879 0.870 0.829 0.885 0.844 
39 0.107 0.624 0.639 0.559 0.851 0.993 0.983 0.725 0.714 0.528 0.314 0.098 0.185 0.420 0.457 0.515 
40 0.413 0.299 0.392 0.426 0.725 0.519 0.702 0.870 0.872 0.708 0.767 0.940 0.977 0.911 0.885 0.938 
41 0.408 0.727 0.952 0.421 0.928 0.970 0.935 0.726 0.332 0.186 0.317 0.050 0.050 0.166 0.461 0.519 
42 0.411 0.815 0.636 0.893 0.845 0.835 0.519 0.329 0.526 0.337 0.320 0.468 0.620 0.710 0.774 0.853 
43 0.858 0.929 0.949 0.812 0.921 0.927 0.940 0.989 0.954 0.984 0.979 0.994 0.999 0.963 0.953 0.848 
44 0.415 0.508 0.828 0.699 0.844 0.993 0.984 0.990 0.961 0.848 0.768 0.315 0.463 0.420 0.457 0.527 
45 0.790 0.814 0.632 0.948 0.973 0.999 0.938 0.719 0.328 0.336 0.471 0.198 0.463 0.576 0.890 0.849 
46 0.233 0.141 0.196 0.058 0.574 0.687 0.530 0.524 0.717 0.705 0.760 0.616 0.763 0.709 0.630 0.695 
47 0.997 0.981 0.974 0.893 0.728 0.683 0.522 0.719 0.173 0.336 0.760 0.873 0.978 0.912 0.985 0.985 
48 0.616 0.728 0.830 0.558 0.414 0.352 0.527 0.521 0.516 0.519 0.464 0.472 0.470 0.282 0.452 0.339 
49 0.712 0.720 0.833 0.814 0.736 0.830 0.699 0.716 0.335 0.344 0.620 0.763 0.872 0.559 0.773 0.714 
50 0.973 0.934 0.394 0.896 0.732 0.693 0.845 0.872 0.958 0.941 0.626 0.461 0.457 0.273 0.181 0.095 
51 0.162 0.519 0.835 0.809 0.970 0.973 0.983 0.954 0.872 0.699 0.310 0.315 0.310 0.272 0.184 0.339 
52 0.110 0.054 0.504 0.561 0.564 0.927 0.852 0.714 0.321 0.344 0.465 0.318 0.467 0.164 0.176 0.192 
53 0.318 0.212 0.278 0.295 0.571 0.921 0.982 0.990 0.959 0.849 0.766 0.318 0.317 0.571 0.623 0.708 
54 0.945 0.931 0.992 0.810 0.972 0.829 0.856 0.957 0.870 0.944 0.941 0.945 0.871 0.712 0.774 0.698 
55 0.862 0.963 0.907 0.810 0.722 0.921 0.980 0.957 0.991 0.941 0.946 0.942 0.942 0.915 0.893 0.946 
56 0.234 0.517 0.286 0.111 0.156 0.112 0.097 0.081 0.172 0.193 0.194 0.189 0.189 0.169 0.300 0.334 
57 0.114 0.209 0.069 0.429 0.269 0.350 0.942 0.864 0.528 0.523 0.620 0.767 0.468 0.278 0.458 0.340 
58 0.859 0.734 0.639 0.291 0.155 0.018 0.014 0.029 0.173 0.517 0.766 0.621 0.620 0.572 0.626 0.335 
59 0.230 0.517 0.745 0.812 0.841 0.923 0.850 0.724 0.331 0.336 0.197 0.315 0.463 0.275 0.464 0.336 
60 0.788 0.625 0.745 0.698 0.929 0.685 0.847 0.875 0.720 0.710 0.625 0.628 0.630 0.279 0.300 0.191 
61 0.317 0.139 0.268 0.189 0.260 0.829 0.844 0.958 0.874 0.853 0.874 0.466 0.626 0.563 0.631 0.519 
62 0.992 0.992 0.905 0.894 0.855 0.699 0.852 0.873 0.719 0.524 0.623 0.766 0.872 0.715 0.889 0.940 
63 0.111 0.093 0.641 0.810 0.410 0.928 0.849 0.956 0.957 0.705 0.872 0.771 0.768 0.719 0.619 0.852 
64 0.613 0.886 0.948 0.813 0.931 0.684 0.849 0.871 0.720 0.938 0.873 0.871 0.765 0.705 0.766 0.510 
65 0.237 0.135 0.185 0.417 0.845 0.975 0.935 0.868 0.719 0.522 0.471 0.618 0.767 0.568 0.779 0.846 
66 0.067 0.211 0.073 0.058 0.725 0.927 0.943 0.723 0.526 0.530 0.321 0.203 0.311 0.570 0.794 0.704 
67 0.861 0.622 0.734 0.977 0.991 0.973 0.940 0.869 0.718 0.853 0.943 0.621 0.316 0.093 0.180 0.039 
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Table IV. Initial statistical analysis of CA125 and MS peak information. 
 
CA125 only CA125 and all peaks 
ta 
No. 
cases 
No. 
errors 
CA125   
P-value 
No. 
errors 
Peak 
used 
Weight 
v/w 
 Main P- 
value 
Conditional 
P-value 
0 68 2 0.0001 1 1 1 0.0001 0.3164 
1 56 4 0.0001 2 7 1 0.0001 0.2446 
2 47 6 0.0001 3 15 -2 0.0001 0.1795 
3 36 8 0.0001 4 15 -2 0.0001 0.0746 
4 27 7 0.0001 4 15 -2 0.0001 0.6734 
5 23 7 0.0008 4 15 -1 0.0006 0.4885 
6 20 6 0.001 4 15 -1 0.0028 0.6973 
7 17 6 0.0071 4 1 -1 0.0141 0.6034 
8 17 5 0.0021 3 1 -1 0.0019 0.1523 
9 20 7 0.0042 5 2 -1 0.0076 0.4497 
10 28 14 0.0503 6 3 -1 0.0003 0.0013 
11 28 15 0.1028 8 3 -1 0.0042 0.0078 
12 28 17 0.3164 10 2 -2 0.0585 0.0658 
13 30 16 0.0895 10 2 -2 0.0168 0.0428 
14 25 16 0.4661 8 2 -2 0.0304 0.0206 
15 20 13 0.5211 6 2 -2 0.0464 0.0609 
16 10 6 0.4406 2 67 +1/0 0.4101 0.5066 
 
aColumns in order are: time t to diagnosis in months; the number of cases (triplets) with 
measurement taken between t and t + 6 months prior to diagnosis; the number of errors when 
classifying triplets with CA125 alone and associated P-value; the minimal number of errors 
when classifying with w log C + v log I(p); most often used peak (see Table II); the ratio of 
weights v/w used in the rule; the main P-value for overall significance of this result; the 
conditional P-value for significance of non-CA125 component. Shaded areas show significance 
at P-value <0.05 for CA125 and main P-values beyond 9 months. 
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Table V. Experimental results for triplet classification with a fixed peak (peak 2 or 3) and 
CA125. Results for prediction by CA125 alone (columns 3-4), CA125 and peak 2 (columns 5–8) 
or CA125 and peak 3 (columns 9–12) are shown for each time to diagnosis group. 
 
CA125 only CA125 and peak 2 CA125 and peak 3 
t 
No. 
cases Errorb 
CA125     
P- 
value Rulea Errorb 
Main       
P- 
value 
Conditional 
P-valuec Rulea Errorb 
Main      
P- 
value 
Conditional 
P-valuec 
0 68 2 0.0001 2CA-p02 2 0.0007 1 2CA-p03 2 0.0015 1 
1 56 4 0.0001 2CA-p02 4 0.0007 1 CA+p03 4 0.0015 1 
2 47 6 0.0001 2CA-p02 5 0.0007 1 2CA-p03 5 0.0015 1 
3 36 8 0.0001 2CA-p02 7 0.0007 1 2CA-p03 7 0.0015 1 
4 27 7 0.0001 2CA-p02 6 0.0007 1 CA+p03 6 0.0015 1 
5 23 7 0.0008 CA-p02 6 0.0026 1 2CA-p03 6 0.0104 1 
6 20 6 0.001 CA-p02 5 0.0066 1 CA-p03 6 0.0681 1 
7 17 6 0.0071 CA-p02 4 0.0112 1 CA-p03 5 0.1451 1 
8 17 5 0.0021 CA-p02 4 0.0132 1 CA-p03 4 0.0296 1 
9 20 7 0.0042 CA-p02 5 0.0066 0.5461 CA-p03 5 0.0133 1 
10 28 14 0.0503 CA/2-p02 7 0.0007 0.0046 CA-p03 6 0.0015 0.003 
11 28 15 0.1028 CA/2-p02 9 0.0053 0.0132 CA-p03 8 0.0059 0.0074 
12 28 17 0.3164 CA/2-p02 10 0.0217 0.0296 CA-p03 10 0.0725 0.0725 
13 30 16 0.0895 CA/2-p02 10 0.0046 0.0092 CA-p03 10 0.0222 0.0237 
14 25 16 0.4661 CA/2-p02 8 0.0099 0.0072 CA-p03 10 0.4456 0.268 
15 20 13 0.5211 CA/2-p02 6 0.0145 0.0072 CA-p03 8 0.8542 1 
16 10 6 0.4406 CA/2+p02 5 1 1 CA/2+p03 5 1 1 
 
aThe ‘rule’ columns show the best rules selected: CA in these columns means log C, p02 means 
log I(2), p03 means log I(3). bThe number of errors is shown for the best rule with the associated 
main P-value and conditional P-value. cConditional P-value shows the improvement achieved by 
adding information from peak 2 or 3 beyond 9 months. P-values were multiplied by adjustment 
coefficients 4ζ(2)=6.579 for peak 2 and 9ζ(2)=14.804 for peak 3. The same table with non-
adjusted P-values is shown in Supplementary Information, Table S1. 
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Figure Legends 
Figure 1. A: Processed full-mass range MS spectra for example case (red) and healthy control 
(green) samples. The spectra are averaged from 10 replicate acquisitions per sample. Peak 2 
(m/z 7772) and peak 3 (m/z 9297) are indicated by arrows. B: Processed MS data for peak 2 
(m/z 7772) and peak 3 (m/z 9297) plotted for all samples. Red is controls, blue is cases. 
 
Figure 2. A: Comparison of rules log C and log C − 2 log I(2) for peak 2 on time/case scale. B: 
Comparison of rules log C and log C − log I(3) for peak 3 on time/case scale. A circle means 
that a triplet was correctly classified by both rules. A cross means misclassification in both 
cases. A triangle upwards shows improvement and downwards shows deterioration after 
addition of the − log I(p) component. The figures demonstrate that most samples where addition 
of a peak to CA125 is beneficial (marked as upward triangles) are in the interval of 13–16 
months before the diagnosis (dashed vertical lines). 
 
Figure 3. A: Median dynamics of rules log C and log C − 2 log I(2) for cases only. B: Median 
dynamics of rules log C and log C − log I(3) for cases only. 
 
Figure 4. A: Scatter dot plots for serum levels of platelet factor 4 (PF4) measured by ELISA for 
cases and matched controls in groups with different times to diagnosis. The horizontal bars 
indicate mean values. Significant changes between case groups are indicated. B: Continuous 
time to diagnosis data plotted for CA125. LOWESS curve fitting was applied to the CA125 data 
(solid lines) C: Continuous time to diagnosis data plotted for PF4. D: PF4 and CA125 data were 
plotted against one another (for cases only). Linear regression curve fitting was applied to the 
PF4/CA125 plot (dashed line).  
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